Table 2 |
||||
|
Clinical and laboratory adverse events probably associated with the antimalarial treatment by study group that were recorded at least once during follow up. |
||||
| Adverse event1 |
Amodiaquine/Placebo |
Amodiaquine/Artesunate |
||
|
|
||||
| N = 34 |
(%) |
N = 31 |
(%) |
|
|
|
||||
| Leucopaenia |
18 |
(52,9) |
13 |
(41,9) |
| Neutropaenia |
16 |
(47,1) |
15 |
(48,4) |
| Anaemia |
10 |
(29,4) |
7 |
(22,6) |
| ALT> 48 U/L |
6 |
(17,6) |
4 |
(12,9) |
| Vomit |
5 |
(14,7) |
2 |
(6,5) |
| Dizziness |
5 |
(14,7) |
6 |
(19,4) |
| Abdominal pain |
5 |
(14,7) |
4 |
(12,9) |
| Bilirubin >1 mg/dL |
5 |
(14,7) |
6 |
(19,4) |
| Itching |
4 |
(11,8) |
4 |
(12,9) |
| Headache |
3 |
(8,8) |
0 |
(0) |
| Diarrhoea |
2 |
(5,9) |
2 |
(6,5) |
| Anorexia |
2 |
(5,9) |
1 |
(3,2) |
| Nausea |
1 |
(2,9) |
3 |
(9,7) |
|
|
||||
|
1Definitions: leucopaenia (WBC<5,000/mm3), neutropaenia (total neutrophils<2,000/mm3), anaemia (haemoglobin <12 g/dL). ALT: Alanine Amino Transferase |
||||
|
Osorio et al. Malaria Journal 2007 6:25 doi:10.1186/1475-2875-6-25 |
||||
